Treatment of Aortic Valve Thickening (Aortic Stenosis) in Elderly Patients with Cardiovascular Disease

Introduction to Aortic Stenosis Management

The American College of Cardiology recommends aortic valve replacement (either TAVR or SAVR) as the definitive treatment for elderly patients with symptomatic severe aortic stenosis and cardiovascular disease, improving survival and relieving symptoms, with TAVR preferred in patients with frailty, significant comorbidities, or anatomical factors that increase surgical risk 1, 2

Intervention is appropriate for all symptomatic patients with severe aortic stenosis, regardless of surgical risk, as this improves both mortality and quality of life, according to the American College of Cardiology 1, 2
The American College of Cardiology suggests that TAVR is appropriate for patients with frailty not captured by standard risk scores, porcelain aorta or hostile chest, significant comorbidities, or advanced age with multiple comorbidities 1, 2, 3, 4
The American College of Cardiology recommends SAVR for patients with low to moderate surgical risk, normal coronary arteries, and preserved LV function, as it results in better outcomes 1, 2, 3, 4

The American College of Cardiology suggests intervention in asymptomatic patients when there is evidence of very severe AS, rapid disease progression, or significant valve calcification, as indicated by aortic velocity >4.5-5 m/s or mean gradient >50 mmHg 5

The American Heart Association recommends medical therapy for symptomatic relief in select scenarios, including heart failure symptoms, angina, atrial fibrillation, and acute pulmonary edema, using cautious doses of diuretics, digitalis, ACE inhibitors, nitrates, and beta-blockers 6, 3, 4
Medical management is appropriate when life expectancy is less than 1 year from non-cardiac causes, or in cases of moderate to severe dementia, advanced cancer, or permanent neurological deficits from stroke, according to the American College of Cardiology 1, 2, 6

The European Society of Cardiology recommends standard antithrombotic therapy after TAVR, consisting of clopidogrel 75 mg daily for 3-6 months plus aspirin 75-100 mg daily lifelong, as well as anticoagulation per atrial fibrillation guidelines if chronic AF or other indication exists 7
The European Society of Cardiology suggests echocardiography before discharge, at 30 days, then annually to monitor valve function, and periodic ECG monitoring for new-onset atrial fibrillation 7

The American College of Cardiology advises against delaying intervention in symptomatic severe AS, as survival drops rapidly once symptoms appear 1, 2
The American Heart Association recommends avoiding excessive diuresis in AS patients with heart failure, as the hypertrophied ventricle is preload-dependent and hypotension can result 6, 3, 4
The European Society of Cardiology suggests not assuming asymptomatic status in elderly patients, and performing exercise testing if symptom status is unclear due to deconditioning or comorbidities 1, 2, 5
The American College of Cardiology advises against overlooking concomitant CAD, as it significantly impacts treatment selection and outcomes, particularly with surgical approaches 8
Advanced age alone is not a contraindication to AVR, as valve replacement is technically possible at any age, and outcomes depend more on comorbidities than chronological age, according to the American Heart Association 6, 3, 4, 9

In patients with aortic stenosis, elevated BNP >300 pg/mL is associated with a 7.38-fold increased risk of AS-related events over 5 years, according to the American College of Cardiology 10
ProBNP is a marker of subclinical heart failure and left ventricular decompensation, predictive of symptom onset during follow-up and persistent symptoms after valve replacement, as stated by the American College of Cardiology 10
A fall in systolic blood pressure ≥10 mmHg from baseline to peak exercise or significant decrease in exercise tolerance predicts 60-80% rate of symptom onset within 1-2 years, as recommended by the American College of Cardiology 10

Specifically assess for exertional dyspnea, decreased exercise tolerance, angina, presyncope, or syncope, as recommended by the American College of Cardiology 10
Consider exercise testing if symptom status is unclear, as provoked symptoms on testing indicate the patient is symptomatic and would meet Class I indication for aortic valve replacement, according to the American College of Cardiology 10

Every 6 months for moderate AS (aortic velocity 3.0-3.9 m/s or mean gradient 25-40 mmHg), as recommended by the American College of Cardiology 10
Every 12 months for mild AS (aortic velocity 2.5-2.9 m/s or mean gradient <25 mmHg), according to the American College of Cardiology 10
Monitor left ventricular ejection fraction, as LVEF <60% is associated with >4-fold higher cardiovascular mortality, as stated by the American College of Cardiology 10

Target systolic blood pressure of 120-129 mmHg if tolerated, as recommended by the European Heart Journal 11
ACE inhibitors or ARBs are preferred agents due to potentially beneficial effects on LV fibrosis, control of hypertension, reduction of dyspnea, and improved effort tolerance, according to the American College of Cardiology and the Hypertension journal 12, 13
Beta blockers may be appropriate if concurrent reduced ejection fraction, prior MI, arrhythmias, or angina are present, as recommended by the American College of Cardiology and the Hypertension journal 12, 13

Rising levels or persistently elevated levels >1614 pg/mL indicate worsening subclinical LV dysfunction and increased urgency for intervention, as stated by the European Heart Journal 14
A >30% reduction in BNP with medical management indicates better prognosis, according to the European Heart Journal 14, 15

Proceed to AVR if any symptoms attributable to AS (dyspnea, angina, syncope, heart failure) develop, as recommended by the American College of Cardiology 10
Progression to severe AS (aortic velocity ≥4.0 m/s or mean gradient ≥40 mmHg) even if asymptomatic, particularly if very severe AS with velocity ≥5.0 m/s, as stated by the American College of Cardiology 10